A research facility in RTP is being sold by Dynogen Pharmaceuticals to Tokyo-based Astellas Pharma.
Terms of the sale were not disclosed.
“Dynogen has built a facility with first-class capabilities for evaluating the clinical potential of urological development candidates especially in the area of lower urinary tract disorders,” said Isao Yanagisawa, senior corporate officer of Astellas Pharma. “The acquisition of this research facility will strengthen our capabilities in this key area.”
Dynogen used the facility for preclinical studies related to disorders affecting genitourinary (genital and urinary organs) disorders.
“We’ve built an impressive clinical and preclinical pipeline through our unique understanding of the neuroscience underlying gastrointestinal and genitourinary disorders, leveraging that knowledge to generate strong intellectual property and utilizing that intellectual property to enable an aggressive in-licensing program,” said Lee Brettman, president and chief executive officer of Dynogen. “We’ve maximized the value of the North Carolina facility in this effort, and now will focus all of our efforts on advancing the development of our five clinical programs and our late-stage preclinical programs.”